Ballast Inc. Sells 14,342 Shares of Pfizer Inc. (NYSE:PFE)

Ballast Inc. lowered its holdings in Pfizer Inc. (NYSE:PFE) by 45.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,013 shares of the biopharmaceutical company’s stock after selling 14,342 shares during the quarter. Ballast Inc.’s holdings in Pfizer were worth $490,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. State Street Corp boosted its position in Pfizer by 1.9% in the second quarter. State Street Corp now owns 287,201,692 shares of the biopharmaceutical company’s stock valued at $10,534,558,000 after buying an additional 5,374,611 shares in the last quarter. Moneta Group Investment Advisors LLC boosted its position in Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock valued at $8,257,000,000 after buying an additional 160,963,976 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Pfizer by 10.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after buying an additional 9,393,992 shares in the last quarter. Morgan Stanley boosted its position in Pfizer by 0.4% in the third quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock valued at $2,817,055,000 after buying an additional 348,628 shares in the last quarter. Finally, Norges Bank acquired a new position in Pfizer in the fourth quarter valued at about $3,150,472,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.1 %

Shares of NYSE:PFE opened at $27.75 on Friday. Pfizer Inc. has a 52 week low of $25.61 and a 52 week high of $42.22. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The company has a market capitalization of $157.14 billion, a PE ratio of 77.08, a PEG ratio of 1.24 and a beta of 0.61. The company has a 50 day moving average price of $27.46 and a two-hundred day moving average price of $29.46.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same quarter in the prior year, the firm earned $1.14 earnings per share. The business’s quarterly revenue was down 41.3% on a year-over-year basis. Analysts forecast that Pfizer Inc. will post 2.22 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on PFE shares. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. UBS Group reduced their price target on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a research report on Thursday, December 14th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Friday, March 1st. Truist Financial reduced their target price on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a research report on Thursday, December 14th. Finally, Barclays reduced their target price on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 14th. Twelve research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $36.88.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.